TD2015MRPL

Summary of Major Modifications

The Technical Document on Minimum Required Performance Levels for Detection and Identification of Non-Threshold Substances has undergone a brief revision by WADA’s Laboratory Expert Group (LabEG).

The new version of the document, TD2015MRPL, includes the following modifications:

i) In Table 1, an MRPL at 2 ng/mL has been defined for a new class of substances, namely the Growth Hormone (GH)-Releasing Factors (GHRF), including the GH-Releasing Hormone (GHRH) and its analogues, the GH-Secretagogues (GHS) and the GH-Releasing Peptides (GHRP). These substances are classified under section S2.5 of the Prohibited List.

ii) In Table 1, an MRPL at 2 ng/mL has been defined for desmopressin and its analogs. These substances are classified under section S5: Diuretics and Masking Agents of the Prohibited List.

iii) Under paragraph 4.0, it has been clarified that salmeterol should not be reported at levels below 10 ng/mL (i.e. 50% of the MRPL).

iv) Under paragraph 4.0, it has been clarified that octopamine findings should not be reported at levels below the MRPL of 1000 ng/mL.